eGenesis vs MasterControl
Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA-cleared IND for CRISPR-edited pig kidney (ESKD Phase 1/2/3). First patient dialysis-free at 7+ months post-transplant. 69-gene-edited pig — most complex CRISPR ever.
About
eGenesis is developing gene-edited pig organs for human transplantation — xenotransplantation — using a 69-gene CRISPR editing protocol that simultaneously knocks out pig genes that trigger human rejection, adds human immune tolerance genes, and eliminates porcine endogenous retroviruses. The company received FDA clearance for its IND for EIGEN-2784 (a gene-edited pig kidney) for end-stage kidney disease, and its first transplant patient remained dialysis-free at more than 7 months post-transplant — the longest reported survival for a xenotransplantation recipient.
MasterControl is the leading QMS and MES platform for regulated life sciences industries, serving 1,100+ companies with $200M revenue in 2025; valued at $1.3B after $150M from Sixth Street, acquired Qualer in Mar 2025.
About
MasterControl is a leading provider of quality management system (QMS) and manufacturing execution system (MES) software for regulated industries, with a primary focus on pharmaceuticals, medical devices, biotechnology, and food and beverage. The company's AI-powered platform digitizes and automates compliance-critical workflows including document control, training management, audit management, change control, corrective and preventive action (CAPA), risk management, and electronic batch records — replacing paper-based processes that are error-prone, audit-vulnerable, and incompatible with modern manufacturing velocity.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.